That is incorrect, commercialisation comes about via successful trial results, and the share price ups and downs are more a concern to anxious traders or people who don't know what they bought into.
CEO's role is not primarily Share price and Marketcap in an R&D, it is to stay financially viable for long enough to achieve successful phase trials to commercialisation and to manage staff and expand the company as it progresses and as necessary.
The long COVID study is dynamic, mid-22 can be June, July, August, September, or whenever the results are ready, a CEO can't make trials and tests and collaborations faster than they go, he waits, we wait, not complicated.
ANP is flat because we are in a waiting phase, we wait for results, we wait for trials, we wait for collaborations, we wait for the market to improve, we wait for the world economy to improve, and we wait for the regulatory processes.
Not much selling, not much buying. It's as to be expected, no surprise.
The last announcement was fine, stock standard, and as expected under the current conditions.
Why you would think CG has disappeared is beyond me, she is the Chair and a person with a lot of experience and contacts, she would be doing what she does best, and I don't think that would be making social media posts about her daily activities.
As suggested before I think a handful of people here need to read the ASX company disclosure requirements.
They have given us a roadmap, clearly what they do behind the scenes is to facilitate and progress that clearly stated roadmap. I feel fully informed and many others too, and as an informed shareholder I know I have to wait for stages to progress, and with some luck, all in a positive and productive manner.
If the share price goes up 6 cents tomorrow, what does it do for unhappy punters, makes the portfolio number look better, is that it, because the portfolio number is irrelevant at the moment, the progression of ATL-1102 is what is important? If ATL-1102 progresses successfully the portfolio numbers will look terrific if it doesn't they will not, all should know what they bought into and that is a company without a product that must maintain financial viability until it has a marketable product whether that takes 5 years or 25 years. It may or may not succeed.
Know what you bought into, and we all bought into a chance at a good earn which is incorporated in a waiting game. Patience is mandatory for an R&D Biotech, 100%, or people may lose their marbles.
^^^^ That and everything else Dalts said, all fits and makes sense.
Expand
(20min delay)
